When is pharmacogenetic testing for antidepressant response ready for the clinic? A cost-effectiveness analysis based on data from the STAR*D study - Wikidata - awgldk - TriplyDB

When is pharmacogenetic testing for antidepressant response ready for the clinic? A cost-effectiveness analysis based on data from the STAR*D study

When is pharmacogenetic testing for antidepressant response ready for the clinic? A cost-effectiveness analysis based on data from the STAR*D study

http://www.wikidata.org/entity/Q33459789

about

A Model Based Cost-Effectiveness Analysis of Routine Genotyping for CYP2D6 among Older, Depressed Inpatients Starting Nortriptyline Pharmacotherapy Pilot study of pharmacist-assisted delivery of pharmacogenetic testing in a primary care setting.Towards the clinical implementation of pharmacogenetics in bipolar disorder.Pretreatment brain states identify likely nonresponse to standard treatments for depression.Realities and expectations of pharmacogenomics and personalized medicine: impact of translating genetic knowledge into clinical practice.Methodologies used in cost-effectiveness models for evaluating treatments in major depressive disorder: a systematic review A new paradigm for the prediction of antidepressant treatment response Economic Evaluations of Pharmacogenetic and Pharmacogenomic Screening Tests: A Systematic Review. Second Update of the Literature.Biomarkers predicting treatment outcome in depression: what is clinically significant?Therapygenetics: Using genetic markers to predict response to psychological treatment for mood and anxiety disorders.Testing the McSad depression specific classification system in patients with somatic conditions: validity and performance.Translating biomarkers to clinical practice.Pharmacogenetic testing: Current Evidence of Clinical Utility.Depression symptom dimensions as predictors of antidepressant treatment outcome: replicable evidence for interest-activity symptoms Abandoning personalization to get to precision in the pharmacotherapy of depression.Personalized medicine for depression: can we match patients with treatments?Value of genetic and epigenetic testing as biomarkers of response to antidepressant treatment.The estimation of utility weights in cost-utility analysis for mental disorders: a systematic review.Is individualized medicine more cost-effective? A systematic review.Cost-effectiveness of pharmacogenetic-guided treatment: are we there yet?Rapid evidence review of the comparative effectiveness, harms, and cost-effectiveness of pharmacogenomics-guided antidepressant treatment versus usual care for major depressive disorder.A systematic review and checklist presenting the main challenges for health economic modeling in personalized medicine: towards implementing patient-level models.Influence of CYP2D6 and CYP2C19 gene variants on antidepressant response in obsessive-compulsive disorder.A Framework for Prioritizing Research Investments in Precision Medicine.Clinical efficacy data on gene tests trails marketing in psychiatry.Economic Evaluation of Implementing a Novel Pharmacogenomic Test (IDgenetix®) to Guide Treatment of Patients with Depression and/or Anxiety.A model to incorporate genetic testing (5-HTTLPR) in pharmacological treatment of major depressive disorders.Cost-effectiveness of one-time genetic testing to minimize lifetime adverse drug reactions.Estimation of Input Costs for a Markov Model in a German Health Economic Evaluation of Newer Antidepressants An Introduction to Pharmacogenomics and Personalized Medicine

P2860

Q28468503-8494E2CB-A138-49C3-81B8-4818E00E0727 Q30612258-A8F9B83E-2451-4A4D-8BA2-65FC98F8A6F2 Q33688133-091C39C2-645B-4C4A-AB31-564167C63D91 Q33779403-F34674D0-9B2A-49EA-A9EC-C9227BBD9D10 Q34131354-4893D580-6FB0-411F-880E-4F7152822532 Q34148218-A38FD286-8FAC-4CCC-8928-C59F3DF3897B Q35237120-A67EA103-2478-4FA3-AF0A-A79E95C25074 Q35890606-E3657701-22E3-4B43-B353-E0CDBC87F9C3 Q36593269-74C1BC25-1DAB-4682-A30B-2FF28E2FA065 Q36618462-98421B9F-8DB6-4E5C-A8F5-7FA3E7208488 Q37075455-286870E0-A3BE-45E5-8F91-2372E2722EA7 Q37119173-656AA0BE-8DAB-46FB-8301-E9612E686AFD Q37151528-FDE1B811-6AF2-4E90-82F4-563A71DC0AD1 Q37208565-44242046-7B44-4610-81DA-341A35F3E6A2 Q37274682-C71D664F-861C-4E59-BAF9-227D4D1873B4 Q37789098-CF1AF907-7BEB-46AA-A978-64F601D177E7 Q38154916-5CADC2C9-7824-4467-B8E7-A4581B5A3B02 Q38167693-F502A61F-9539-4C00-8492-99390D814AF8 Q38191496-09D3E5F6-FEDB-4722-9A3F-BB74D3111922 Q38671676-CA5AB968-301F-4A5C-9405-000EBACE0315 Q38812608-FC9B886F-FDDA-4C78-827D-A7FDA5DADFBE Q39039319-10D7316E-D004-4757-80DE-5245C5751638 Q39441964-034A6EF5-F7E0-4327-B7FA-C79E1E32C436 Q40391326-FCE5641C-CB02-496B-9613-F2263290BD0F Q43904208-C5888324-36AE-4DB3-A99D-2C681CF19AE6 Q46956673-DD4E854F-3499-4AB2-9ECE-F593B75F2AC2 Q48868283-E425D220-C533-42DC-B880-BCFE32EAD973 Q53231509-DA2979BA-45E5-4B8C-9982-0195DEAC75C2 Q57148605-510C3699-FE60-4E4D-ACD1-BE77089F1607 Q58875252-2DC0B3C0-33E3-49DF-BCE0-B1AB988ABB93

P2860

When is pharmacogenetic testing for antidepressant response ready for the clinic? A cost-effectiveness analysis based on data from the STAR*D study

http://www.wikidata.org/entity/Q33459789

description

2009 nî lūn-bûn

@nan

2009 թուականի Յունիսին հրատարակուած գիտական յօդուած

@hyw

2009 թվականի հունիսին հրատարակված գիտական հոդված

@hy

2009年の論文

@ja

2009年論文

@yue

2009年論文

@zh-hant

2009年論文

@zh-hk

2009年論文

@zh-mo

2009年論文

@zh-tw

2009年论文

@wuu

name

When is pharmacogenetic testin ...... on data from the STAR*D study

@ast

When is pharmacogenetic testin ...... on data from the STAR*D study

@en

type

label

When is pharmacogenetic testin ...... on data from the STAR*D study

@ast

When is pharmacogenetic testin ...... on data from the STAR*D study

@en

prefLabel

When is pharmacogenetic testin ...... on data from the STAR*D study

@ast

When is pharmacogenetic testin ...... on data from the STAR*D study

@en

P1433

Q33459789-A786C475-59B3-48B7-B97D-32FB59ACF4BC

P1476

Q33459789-20439CC3-0973-4269-98FE-BAE09A34222F

P2093

Q33459789-29975677-0E4C-4825-A435-72D51C906D75

Q33459789-77A2A34E-37DB-4D93-938E-F4C70AD6854C

Q33459789-8E5909CE-B4D0-46DE-A063-7C940DF1D507

Q33459789-C2CB8AB8-2E71-44E1-B373-30F8B689BD50

P2860

Q33459789-0E401D16-69AA-4F41-8137-0D17D540D8D7

Q33459789-17FBFF91-FC95-47A4-A60C-837CDD670333

Q33459789-1BAB3817-F388-4B07-9323-0B696972BF67

Q33459789-1C2939B4-2EFA-4824-AF0B-104C8BC5578D

Q33459789-1D9A4E46-D6D8-4EBC-A0BB-B120CF89CD8D

Q33459789-20514265-B7A3-4573-B474-82AA11A2FC64

Q33459789-267BF969-A6A0-4826-BBE8-A93A098D41AC

Q33459789-294951D0-270D-4B44-99E1-4F3D787E26F7

Q33459789-2A38665E-21ED-430A-ADEA-F60832DE6BD1

Q33459789-3703A8B6-ACF3-41EF-95FF-CB17F293FFFC

P2888

Q33459789-CA8E6A79-20DD-4420-A36E-889373E8D6FC

P304

Q33459789-8F8A8D58-E0A0-4FB0-9D4E-14E72A3E76AF

P31

Q33459789-CD7E7A3E-677F-4F7C-82ED-7C47960DBC24

P356

Q33459789-42A237B4-6041-40B7-83B9-D40CB901563B

P407

Q33459789-38B921A7-B32A-47C4-815D-19679C4ACD0E

P433

Q33459789-6F8BBDF0-AC5C-467C-A5B4-787A1E1374AA

P478

Q33459789-7CDA900C-D8BE-43FF-8192-4C76B20F1D0E

P577

Q33459789-2084783D-3257-4238-931E-C022094782A2

P5875

Q33459789-AB94D930-CE88-44D5-9BD2-490217ABF5EE

P6179

Q33459789-89F75443-8A62-4B0F-9115-63F607A3EFB7

P698

Q33459789-5E0BAE80-36F8-4093-994E-F267FF0F6C2D

P932

Q33459789-8296D05C-930C-4296-A625-8E9E8CCB07A4

P356

P1433

Neuropsychopharmacology

P1476

When is pharmacogenetic testin ...... on data from the STAR*D study

@en

P2093

Amanda Patrick

http://www.w3.org/2001/XMLSchema#string

Jordan W Smoller

http://www.w3.org/2001/XMLSchema#string

Philip S Wang

http://www.w3.org/2001/XMLSchema#string

Roy H Perlis

http://www.w3.org/2001/XMLSchema#string

P2860

Variation in the gene encoding the serotonin 2A receptor is associated with outcome of antidepressant treatment

Phosphodiesterase genes are associated with susceptibility to major depression and antidepressant treatment response

The International HapMap Project

Genetic markers of suicidal ideation emerging during citalopram treatment of major depression

Pharmacogenetic analysis of genes implicated in rodent models of antidepressant response: association of TREK1 and treatment resistance in the STAR(*)D study

The epidemiology of major depressive disorder: results from the National Comorbidity Survey Replication (NCS-R)

Evaluation of outcomes with citalopram for depression using measurement-based care in STAR*D: implications for clinical practice

Acute and longer-term outcomes in depressed outpatients requiring one or several treatment steps: a STAR*D report

Telephone screening, outreach, and care management for depressed workers and impact on clinical and work productivity outcomes: a randomized controlled trial.

Bupropion-SR, sertraline, or venlafaxine-XR after failure of SSRIs for depression.

P2888

P304

2227-2236

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1038/NPP.2009.50

http://www.w3.org/2001/XMLSchema#string

P407

P433

10

http://www.w3.org/2001/XMLSchema#string

P478

34

http://www.w3.org/2001/XMLSchema#string

P577

2009-06-03T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

26265201

http://www.w3.org/2001/XMLSchema#string

P6179

1053634170

http://www.w3.org/2001/XMLSchema#string

P698

19494805

http://www.w3.org/2001/XMLSchema#string

P932

3312011

http://www.w3.org/2001/XMLSchema#string